May 5, 2025, 15:14

John Voight Memorial Leukemia Research Grant

Kids Beating Cancer is now accepting Letters of Intent for the 2025 cycle of the John Voight Memorial Leukemia Research Grant, a competitive two-tiered program totaling up to 300,000 USD over three years. This award is dedicated to accelerating the development of innovative treatments for pediatric leukemia, with a strong focus on Acute Myelocytic Leukemia (AML).

Who is eligible?

Applicants must:

Be based at a U.S. nonprofit or academic research institution
Hold an MD, PhD, or MD/PhD (or equivalent) and a faculty (or equivalent) position
Have a proven track record in pediatric cancer research
Submit original, unpublished work (conference abstracts must show significant updates)
Ensure no budgetary or scientific overlap with other active grants
Postdoctoral researchers are eligible to apply

Funding at a glance:

Tier 1: 100,000 USD for 1 year to demonstrate feasibility and gather pilot data
Tier 2: 200,000 USD for 2 years (invitation-only, contingent on Tier 1 results)
Funds may cover PI salary (within NIH cap), personnel, equipment, and supplies
Indirect costs, administrative expenses, travel, and PR costs are not allowed

Research focus:

The grant supports translational leukemia research aimed at therapeutic development, biomarker discovery, or any innovative intervention with the potential to impact pediatric AML patients within several years.

Key deadlines:

Letter of Intent Due: July 1, 2025
Invitation to Apply Notification: August 1, 2025
Full Proposal Deadline: September 15, 2025
Award Notification: November–December 2025

Where to apply:

All submissions must be made via ProposalCentral. Format and instructions must follow NIH-style standards.

Questions?

Contact:

Sam Azar (COO & VP of Research) – [email protected]
Ian Henrich, PhD (Chair, Scientific Advisory Board) – [email protected]

acute myelocytic leukemia AML therapy development biomarker research cancer Childhood Cancer John Voight Memorial Grant Kids Beating Cancer Leukemia Research OncoDaily pediatric AML pediatric oncology proposalCENTRAL research grant Translational Oncology US academic researchers

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment